Sentry LLC’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$472K Hold
3,010
0.13% 77
2026
Q1
$460K Hold
3,010
0.15% 73
2025
Q4
$415K Hold
3,010
0.11% 79
2025
Q3
$386K Hold
3,010
0.1% 84
2025
Q2
$364K Hold
3,010
0.07% 87
2025
Q1
$336K Hold
3,010
0.07% 90
2024
Q4
$293K Hold
3,010
0.06% 95
2024
Q3
$346K Sell
3,010
-35
-1% -$3.97K 0.07% 91
2024
Q2
$324K Hold
3,045
0.06% 86
2024
Q1
$295K Hold
3,045
0.06% 95
2023
Q4
$307K Hold
3,045
0.07% 90
2023
Q3
$310K Hold
3,045
0.07% 91
2023
Q2
$307K Hold
3,045
0.07% 98
2023
Q1
$280K Buy
+3,045
New +$266K 0.07% 96

Other funds holding NVS

Sentry LLC's NVS Position: Q2 2026 in Review

Sentry LLC held its Novartis (NVS) position steady in Q2 2026 at 3,010 shares worth $472K. The position accounts for 0.13% of the portfolio, ranked #77.

Sentry LLC first reported a position in NVS in Q1 2023 and has held it in 14 quarters since. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Sentry LLC held 3,010 shares of Novartis worth $472K as of Q2 2026.
  • Sentry LLC left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.13% of Sentry LLC's portfolio in Q2 2026, its #77 holding.
  • Sentry LLC first reported a position in Novartis in Q1 2023 and has held it in 14 quarters since.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Sentry LLC's 13F filing for Q2 2026, filed 14 Aug 2026.